Q-omics provides the consensus-scored TMC7 profile across patient tissues and cancer cell-line models. TMC7 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, TMC7 is differentially expressed in 15, with the highest sampling consensus in HNSC. Additionally, TMC7 RNA expression shows 19,318 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight MESO, HNSC, and UVM as cancer lineages where TMC7 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TMC7 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TMC7 survival associations across molecular data types. TMC7 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (5) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TMC7 RNA expression–survival associations across cancer types. High TMC7 expression shows unfavorable associations in MESO, KIRP, LIHC and ACC, but favorable associations in KIRC and BLCA. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for TMC7 RNA expression.
This table summarizes TMC7 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 1. The strongest signals are observed in HNSC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for TMC7. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TMC7 shows lower tumor expression in LUSC and higher tumor expression in HNSC, KIRC, STAD, LIHC and PAAD. The HNSC box plot shows higher TMC7 RNA expression in tumor versus normal tissue (log2 FC = +1.671, t-test p < 0.001).
This table shows molecular features associated with TMC7 in patient tissues and cancer cell lines. In patient samples, TMC7 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, TMC7 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in URINARY_TRACT and UPPER_AERODIGESTIVE_TRACT.
